Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

Chi V. Dang

doi:10.1016/j.ccr.2009.10.001

Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

Chi V. Dang

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

Abstract

In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

Original language	English (US)
Pages (from-to)	361-362
Number of pages	2
Journal	Cancer cell
Volume	16
Issue number	5
DOIs	https://doi.org/10.1016/j.ccr.2009.10.001
State	Published - Nov 6 2009

ASJC Scopus subject areas

Oncology
Cancer Research
Cell Biology

Access to Document

10.1016/j.ccr.2009.10.001

Cite this

@article{1bb0c02c607d4469bfc08c31ce4fadbf,

title = "Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer",

abstract = "In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.",

author = "Dang, {Chi V.}",

year = "2009",

month = nov,

day = "6",

doi = "10.1016/j.ccr.2009.10.001",

language = "English (US)",

volume = "16",

pages = "361--362",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

AU - Dang, Chi V.

PY - 2009/11/6

Y1 - 2009/11/6

N2 - In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

AB - In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=70350492579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350492579&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2009.10.001

DO - 10.1016/j.ccr.2009.10.001

M3 - Short survey

C2 - 19878865

AN - SCOPUS:70350492579

SN - 1535-6108

VL - 16

SP - 361

EP - 362

JO - Cancer cell

JF - Cancer cell

IS - 5

ER -

Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this